Your browser is no longer supported. Please, upgrade your browser.
Settings
GALE Galena Biopharma, Inc. daily Stock Chart
GALE [NASD]
Galena Biopharma, Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own0.40% Shs Outstand40.00M Perf Week-4.95%
Market Cap15.59M Forward P/E- EPS next Y-0.84 Insider Trans-0.31% Shs Float36.70M Perf Month11.73%
Income-15.70M PEG- EPS next Q-0.15 Inst Own28.30% Short Float10.75% Perf Quarter-33.26%
Sales- P/S- EPS this Y77.80% Inst Trans- Short Ratio5.87 Perf Half Y-32.62%
Book/sh0.51 P/B0.76 EPS next Y-42.40% ROA-48.30% Target Price8.00 Perf Year-92.76%
Cash/sh0.45 P/C0.86 EPS next 5Y- ROE-131.70% 52W Range0.26 - 6.98 Perf YTD-79.91%
Dividend- P/FCF- EPS past 5Y9.90% ROI- 52W High-94.41% Beta2.02
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin- 52W Low51.74% ATR0.02
Employees14 Current Ratio0.90 Sales Q/Q- Oper. Margin- RSI (14)54.64 Volatility4.31% 6.55%
OptionableYes Debt/Eq0.68 EPS Q/Q-121.30% Profit Margin- Rel Volume0.36 Prev Close0.39
ShortableYes LT Debt/Eq0.00 EarningsNov 13 AMC Payout- Avg Volume672.57K Price0.39
Recom3.00 SMA202.33% SMA506.95% SMA200-43.29% Volume244,036 Change0.72%
Feb-06-17Downgrade FBR & Co. Outperform → Mkt Perform $11 → $4
Feb-02-17Downgrade Maxim Group Buy → Hold
Dec-02-16Reiterated Maxim Group Buy $1 → $4
Aug-10-16Reiterated Maxim Group Buy $2 → $1
Jul-22-16Reiterated FBR Capital Outperform $5 → $2
Jul-11-16Reiterated Maxim Group Buy $4 → $2
Jun-29-16Downgrade Raymond James Outperform → Mkt Perform
Dec-22-15Reiterated Maxim Group Buy $7 → $4
Dec-08-15Upgrade Cantor Fitzgerald Sell → Hold
Nov-12-15Upgrade Oppenheimer Perform → Outperform $4
Nov-10-15Reiterated ROTH Capital Buy $8 → $6
Sep-09-15Initiated Raymond James Outperform
Mar-09-15Reiterated Needham Buy $7 → $4
Nov-20-14Reiterated MLV & Co Buy $3 → $5
Aug-22-14Reiterated MLV & Co Buy $5 → $3.50
Aug-12-14Reiterated Needham Buy $9 → $7
Feb-03-14Reiterated Noble Financial Buy $4 → $6
Jan-21-14Reiterated Maxim Group Buy $9 → $11
Jan-08-14Reiterated Maxim Group Buy $6 → $9
Nov-26-13Initiated Oppenheimer Outperform $6
Oct-02-17 07:35AM  SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA PR Newswire +6.92%
Sep-28-17 07:05AM  Galena Biopharma Announces Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with Trastuzumab GlobeNewswire
Sep-20-17 09:45AM  How Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio? Simply Wall St.
Sep-11-17 07:05AM  Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership GlobeNewswire
Sep-08-17 04:36PM  Galena settles U.S. kickback charges related to opioid drug Reuters
04:01PM  Galena settles U.S. kickback charges related to opioid drug Reuters
Aug-14-17 09:54PM  Galena Biopharma reports 2Q loss Associated Press +9.04%
04:30PM  Galena Biopharma Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-10-17 07:00AM  Featured Company News - Galena Biopharma Announces Merger Agreement with SELLAS Life Sciences Group ACCESSWIRE -5.80%
Aug-09-17 08:10AM  Today's Research Reports on Stocks to Watch: Depomed Inc. and Galena Biopharma ACCESSWIRE -7.07%
Aug-08-17 06:00AM  Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group GlobeNewswire -26.55%
Jul-12-17 06:30AM  Galena Biopharma Provides Corporate Update GlobeNewswire
Jun-29-17 12:26PM  Top 10 Penny Stocks To Buy in 2017 Insider Monkey
May-15-17 10:30AM  AbbVie and J&J Present Positive Imbruvica Leukemia Data Zacks
May-10-17 06:06PM  Galena Biopharma reports 1Q loss Associated Press
04:30PM  Galena Biopharma Reports First Quarter 2017 Financial Results GlobeNewswire
01:52PM  Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View Zacks
May-05-17 10:06AM  Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss Zacks +5.64%
10:04AM  Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus Zacks
Apr-21-17 09:30AM  Zacks.com featured highlights: Galena Biopharma, EVINE Live, Sanchez Production Partners, Bazaarvoice and Avon Products Zacks
Apr-19-17 10:38AM  Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III Zacks
Apr-13-17 12:30PM  DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm Accesswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline - April 14, 2017 GlobeNewswire
Apr-12-17 03:45PM  FRIDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
01:34PM  GALE APRIL 14 ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action - GALE PR Newswire
Apr-11-17 01:46PM  For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1 TheStreet.com
Apr-10-17 03:26PM  SEC Targets Fraud on Stock Tip-Sheet Websites The Wall Street Journal
02:00PM  4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm Accesswire
11:55AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Galena Biopharma, Inc. to Contact the Firm Accesswire
Apr-05-17 02:00PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
02:00PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
01:52PM  Deadline Alert: GPM Reminds Investors of the April 14 Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc. Business Wire
01:52PM  Deadline Alert: GPM Reminds Investors of the April 14 Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
10:37AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017 Accesswire
10:37AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017
09:30AM  Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy Zacks
09:30AM  Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy
Apr-04-17 10:45PM  DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Galena Biopharma, Inc. To Contact The Firm Business Wire +6.60%
10:45PM  DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Galena Biopharma, Inc. To Contact The Firm
03:18PM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm Accesswire
03:18PM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
01:43PM  April 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Galena Biopharma, Inc. Investors of Upcoming Lead Plaintiff Deadline Business Wire
01:43PM  April 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Galena Biopharma, Inc. Investors of Upcoming Lead Plaintiff Deadline
11:49AM  Galena's Breast Cancer Drug Combo Deemed Safe Investopedia
11:49AM  Galena's Breast Cancer Drug Combo Deemed Safe
07:05AM  Galena Biopharma Presents Positive Interim Safety Data on the NeuVax (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017 GlobeNewswire
07:05AM  Galena Biopharma Presents Positive Interim Safety Data on the NeuVax (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
Apr-03-17 06:17PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
05:26PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib
04:28PM  Bayer Announced Positive Data for Cancer Drug Copanlisib
04:11PM  GlaxoSmithKline Initiates Phase III Study with Mepolizumab
03:47PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Galena Biopharma, Inc. To Contact The Firm PR Newswire
Mar-31-17 07:14PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Encourages Investors with Losses Over $100,000 to Contact the Firm GlobeNewswire
05:20PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Galena Biopharma, Inc. - GALE PR Newswire
Mar-30-17 02:11PM  Roche's Rituxan Gets FDA Advisory Committee's Recommendation
02:11PM  Roche's Rituxan Gets FDA Advisory Committee's Recommendation
11:30AM  Acorda Presents Data for Parkinson's Candidate CVT-301
11:30AM  Acorda Presents Data for Parkinson's Candidate CVT-301 at Investopedia
09:46AM  Amgen's Leukemia Drug Accepted for Priority Review by FDA at Investopedia
Mar-29-17 04:51PM  Corcept (CORT) Strives to Commercialize Key Drug Korlym
11:18AM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:45AM  Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III
10:37AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017 Accesswire
Mar-28-17 05:19PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan
Mar-27-17 02:27PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Galena Biopharma, Inc. and Encourages Investors With Losses to Contact the Firm Business Wire +6.01%
Mar-24-17 07:01PM  Lifshitz & Miller LLP Announces Investigation of Air Methods Corporation, Fortress Investment Group LLC, Galena Biopharma, Inc., Ionis Pharmaceuticals, Inc., LMI Aerospace, Inc., Lumos Networks Corp., Silver Bay Realty Trust Corp. and Terra PR Newswire
Mar-23-17 04:45PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
12:33PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm Accesswire
10:36AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline: April 14, 2017 Accesswire
Mar-21-17 01:04PM  GALENA BIOPHARMA, INC. Financials -5.75%
Mar-20-17 11:04AM  SHAREHOLDR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm Accesswire
10:34AM  New Strong Buy Stocks for March 20th
09:30AM  Today's Research Reports on Stocks to Watch: Geron and Galena Biopharma Accesswire
Mar-17-17 05:13PM  GALE STOCK LOSS: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action GALE GlobeNewswire
02:03PM  Pawar Law Group Announces Filing of Securities Class Action Lawsuit Against Galena Biopharma, Inc. - GALE Accesswire
10:49AM  Galena Ovarian Cancer Drug Reports Positive Data at Investopedia
07:05AM  Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data GlobeNewswire
Mar-16-17 12:51PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +6.75%
10:26AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline: April 14, 2017 Accesswire
Mar-15-17 07:25PM  Galena Biopharma reports 4Q loss +5.81%
07:17PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Galena Biopharma, Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire
04:18PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
04:15PM  Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update GlobeNewswire
07:07AM  Q4 2016 Galena Biopharma Inc Earnings Release - After Market Close
Mar-13-17 04:58PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-10-17 10:45AM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline: April 14, 2017 GlobeNewswire
Mar-09-17 07:05AM  Galena Biopharma Engages Canaccord Genuity to Advise on Strategic Alternatives GlobeNewswire
Mar-07-17 11:18AM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:00AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Galena Biopharma, Inc. (GALE) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit GlobeNewswire
Mar-06-17 01:43PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-03-17 03:59PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Galena Biopharma, Inc. GALE GlobeNewswire
Mar-02-17 10:26AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline: April 14, 2017 Accesswire
Feb-27-17 11:30AM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Feb-26-17 06:00PM  INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Galena Biopharma, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Feb-24-17 06:00PM  IMPORTANT GALENA BIOPHARMA, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of New Jersey against Galena Biopharma, Inc. GlobeNewswire +6.78%
Feb-23-17 04:59PM  How to Dig Deep for Value in These Exuberant Markets
02:00PM  Value Investors Have to Go Deeper
12:06PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:25AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline: April 14, 2017 Accesswire
Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer. In addition, the company develops GALE-301 and GALE-302 for ovarian, endometrial, and breast cancers. It has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nisi RudolphDirectorJun 20Sale0.5550027314,864Jun 22 05:37 PM
Hudson Bay Capital Management 10% OwnerFeb 08Sale0.842,363,4411,985,2902,036,559Feb 10 06:16 PM